Terrell A Suddarth

US Patent:

20110129520, Jun 2, 2011

Filed:

Apr 23, 2009

Appl. No.:

12/428836

Inventors:

Simon Bogdansky - Littleton CO, US
Chad Ronholdt - Aurora CO, US
Adrian Samaniego - Louisville CO, US
Kenneth Blood - Littleton CO, US
Terrell Suddarth - Winchester TN, US

International Classification:

A61L 15/16
A61K 35/48

US Classification:

424446, 424582

Abstract:

An anti-adhesion wound barrier fabricated from amnion obtained from human birth tissue and treated with a glutaraldehyde solution is provided. The amnion is treated in 1% glutaraldehyde solution for up to 15 minutes to fix the amnion. Methods of processing the birth tissue to prepare the amnion for use as a wound barrier are also provided. Use of the amnion anti-adhesion wound barrier for dressing wounds is also described.

US Patent:

20210338447, Nov 4, 2021

Filed:

Dec 14, 2020

Appl. No.:

17/247490

Inventors:

- Franklin MA, US
Terrell SUDDARTH - New Market AL, US
Harold SCHOENHAUS - Delray FL, US

Assignee:

Arthrosurface, Inc. - Franklin MA

International Classification:

A61F 2/42
A61L 27/36

Abstract:

Provided is a system and method for providing a non-binding allograft subtalar joint implant for surgical implant into a person's foot proximate to the ankle. This system for repair includes at least one sterile non-binding allograft subtablar joint implant provided as a pre-formed allograft rod plug “ARP” having a diameter about equal to an average width of a canal between a person's talus and calcaneus bones, the ARP being resiliently compressible and flexible. When snuggly disposed between the person's talus and calcaneus bones, the ARP compresses during normal use of the person's foot and maintains the canal in an anatomically correct alignment and reduces a tendency for abnormal motion between the person's talus and calcaneus bones. An associated method of use is also provided.

US Patent:

20200155613, May 21, 2020

Filed:

Dec 30, 2019

Appl. No.:

16/730877

Inventors:

- Phoenix AZ, US
Terrell Suddarth - New Market AL, US
Bruce Werber - Ft Lauderdale FL, US

International Classification:

A61K 35/50
A61L 27/36
A61K 31/728
A61K 35/35

Abstract:

Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

US Patent:

20190350984, Nov 21, 2019

Filed:

Jul 29, 2019

Appl. No.:

16/525062

Inventors:

- Phoenix AZ, US
Terrell Suddarth - Winchester TN, US
Bruce Werber - Phoenix AZ, US

International Classification:

A61K 35/50
A61K 35/545
A61K 9/14
A61K 8/98
A61K 35/28
A61F 9/00
A61M 5/178
A61M 11/00
A61J 1/14
A61K 47/46
A61K 47/20
A61Q 19/08
A61K 8/02
C12N 5/073
A61K 35/44
A61K 35/35

Abstract:

A frozen therapeutic dose includes an amniotic material and is configured into a pack for easy administering of the dose to a treatment location. A frozen therapeutic dose may contain a concentration of live amniotic stem cells. A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic. A frozen therapeutic dose package may be kept in a conventional freezer at −20 C., for example, for extended periods of time and a person may remove the package as needed for treatment. A frozen dose package or pack may contain a secondary material configured to mix with the frozen therapeutic dose. A secondary material may be configured within a single dose compartment with the frozen dose or within a separate compartment.

US Patent:

20190269520, Sep 5, 2019

Filed:

Oct 9, 2018

Appl. No.:

16/155563

Inventors:

- Fort Lauderdale FL, US
Terrell Suddarth - New Market AL, US
Harold Schoenhaus - Delray FL, US

International Classification:

A61F 2/42
A61L 27/36

Abstract:

Provided is a system and method for providing a non-binding allograft subtalar joint implant for surgical implant into a person's foot proximate to the ankle. This system for repair includes at least one sterile non-binding allograft subtalar joint implant provided as a pre-formed allograft rod plug “ARP” having a diameter about equal to an average width of a canal between a person's talus and calcaneus bones, the ARP being resiliently compressible and flexible. When snuggly disposed between the person's talus and calcaneus bones, the ARP compresses during normal use of the person's foot and maintains the canal in an anatomically correct alignment and reduces a tendency for abnormal motion between the person's talus and calcaneus bones. An associated method of use is also provided.

US Patent:

20180271915, Sep 27, 2018

Filed:

Sep 14, 2015

Appl. No.:

15/542444

Inventors:

- Phoenix AZ, US
Terrell Suddarth - New Market AL, US
Bruce Werber - Ft Lauderdale FL, US

International Classification:

A61K 35/50
A61K 35/35
A61K 31/728

Abstract:

Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

US Patent:

20180177601, Jun 28, 2018

Filed:

Feb 12, 2018

Appl. No.:

15/894102

Inventors:

- Fort Lauderdale FL, US
Terrell SUDDARTH - New Market AL, US
Harold SCHOENHAUS - Delray FL, US

International Classification:

A61F 2/42
A61L 27/36

Abstract:

Provided is a system and method for providing a non-binding allograft subtalar joint implant for surgical implant into a person's foot proximate to the ankle. This system for repair includes at least one sterile non-binding allograft subtablar joint implant provided as a pre-formed allograft rod plug “ARP” having a diameter about equal to an average width of a canal between a person's talus and calcaneus bones, the ARP being resiliently compressible and flexible. When snuggly disposed between the person's talus and calcaneus bones, the ARP compresses during normal use of the person's foot and maintains the canal in an anatomically correct alignment and reduces a tendency for abnormal motion between the person's talus and calcaneus bones. An associated method of use is also provided.

US Patent:

20170189197, Jul 6, 2017

Filed:

Dec 30, 2015

Appl. No.:

14/985125

Inventors:

- Phoenix AZ, US
Terrell SUDDARTH - New Market AL, US
Herold SCHOENHAUS - Delray FL, US

International Classification:

A61F 2/42
A61L 27/36

Abstract:

Provided is a system and method for providing a non-binding allograft subtalar joint implant for surgical implant into a person's foot proximate to the ankle. This system for repair includes at least one sterile non-binding allograft subtablar joint implant provided as a pre-formed allograft rod plug “ARP” having a diameter about equal to an average width of a canal between a person's talus and calcaneus bones, the ARP being resiliently compressible and flexible. When snuggly disposed between the person's talus and calcaneus bones, the ARP compresses during normal use of the person's foot and maintains the canal in an anatomically correct alignment and reduces a tendency for abnormal motion between the person's talus and calcaneus bones. An associated method of use is also provided.